-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $44

Benzinga·11/11/2026 14:09:08
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $42 to $44.